Abstract
The widespread use of biologics has paved way for newer options in therapeutics for once incurable illnesses. Their large and complex protein structure, post-translational modifications, elaborate manufacturing/production process and risk for immunogenicity adds to the uniqueness of a biologic product. Patent expiration of innovator biologics has led to the development of biosimilars; biologics similar/comparable to the reference product in terms of quality, safety and efficacy. We discuss the clinical safety and regulatory requirements for biosimilars in various countries across the world. Future holds promise for biosimilars to provide affordable, efficacious and safe treatment to a vast majority of patients with significant cost savings to the nation.
Keywords: Biologic, biosimilar, immunogenicity, patent, regulation, safety.
Current Clinical Pharmacology
Title:Biosimilars: Current Scientific and Regulatory Considerations
Volume: 9 Issue: 1
Author(s): Preeta Kaur Chugh and Vandana Roy
Affiliation:
Keywords: Biologic, biosimilar, immunogenicity, patent, regulation, safety.
Abstract: The widespread use of biologics has paved way for newer options in therapeutics for once incurable illnesses. Their large and complex protein structure, post-translational modifications, elaborate manufacturing/production process and risk for immunogenicity adds to the uniqueness of a biologic product. Patent expiration of innovator biologics has led to the development of biosimilars; biologics similar/comparable to the reference product in terms of quality, safety and efficacy. We discuss the clinical safety and regulatory requirements for biosimilars in various countries across the world. Future holds promise for biosimilars to provide affordable, efficacious and safe treatment to a vast majority of patients with significant cost savings to the nation.
Export Options
About this article
Cite this article as:
Chugh Kaur Preeta and Roy Vandana, Biosimilars: Current Scientific and Regulatory Considerations, Current Clinical Pharmacology 2014; 9 (1) . https://dx.doi.org/10.2174/15748847113089990066
DOI https://dx.doi.org/10.2174/15748847113089990066 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Translocator Protein Ligands as Promising Therapeutic Tools for Anxiety Disorders
Current Medicinal Chemistry Sudden Infant Death Syndrome: Implications of Altered Physiological Control During Sleep
Current Pediatric Reviews Lessons from Nature: Sources and Strategies for Developing AMPK Activators for Cancer Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry New Perspectives in the Management of Secondary Hyperparathyroidism
Mini-Reviews in Medicinal Chemistry Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)
Current Medicinal Chemistry A Novel Immunotherapy for Alzheimers Disease: Antibodies against the β-Secretase Cleavage Site of APP
Current Alzheimer Research C-Peptide and its Correlation to Parameters of Insulin Resistance in the Metabolic Syndrome
CNS & Neurological Disorders - Drug Targets Meet Our Regional Editor
Mini-Reviews in Medicinal Chemistry Chimeric Virus-like Particles of Universal Antigen Epitopes of Coronavirus and Phage Qβ Coat Protein Trigger the Production of Neutralizing Antibodies
Current Topics in Medicinal Chemistry Metabolomic and Imaging: A Literature Review
Current Medical Imaging Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?
Current Diabetes Reviews Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview
Anti-Cancer Agents in Medicinal Chemistry 25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages
Current Pharmaceutical Design Possible Involvement of Muscarinic Receptors in Psychiatric Disorders: A Focus on Schizophrenia and Mood Disorders
Current Molecular Medicine Sirtuins Family- Recent Development as a Drug Target for Aging, Metabolism, and Age Related Diseases
Current Drug Targets Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Animal Models for Studying Neointima Formation
Current Vascular Pharmacology